Pfizer but it doesn't matter, it could happen with or without vaccination, Covid itself can cause serious health problems.
Fortunately most of the supplements that help MSers work on him too!
Coronavirus (COVID-19) Research
Re: Coronavirus (COVID-19) Research
Here's a comparison of the covid19 death rates of unvaccinated vs. vaccinated patients.
https://ourworldindata.org/grapher/unit ... ion-status
This difference in the vaccinated vs. unvaccinated death rates are supported by more recent data which showed a 97x reduction for those who are vaccinated.
https://www.factcheck.org/2022/02/scich ... ed-adults/
https://ourworldindata.org/grapher/unit ... ion-status
This difference in the vaccinated vs. unvaccinated death rates are supported by more recent data which showed a 97x reduction for those who are vaccinated.
https://www.factcheck.org/2022/02/scich ... ed-adults/
Re: Coronavirus (COVID-19) Research
Report: COVID-19 vaccines saved US $1.15 trillion, 3 million lives
News brief December 13, 2022
https://www.cidrap.umn.edu/covid-19/rep ... lion-lives
"Without vaccination the U.S. would have experienced 1.5 times more infections, 3.8 times more hospitalizations, and 4.1 times more deaths," the authors wrote. "These losses would have been accompanied by more than $1 trillion in additional medical costs that were averted because of fewer infections, hospitalizations, and deaths."
News brief December 13, 2022
https://www.cidrap.umn.edu/covid-19/rep ... lion-lives
"Without vaccination the U.S. would have experienced 1.5 times more infections, 3.8 times more hospitalizations, and 4.1 times more deaths," the authors wrote. "These losses would have been accompanied by more than $1 trillion in additional medical costs that were averted because of fewer infections, hospitalizations, and deaths."
Re: Coronavirus (COVID-19) Research
What about with no vaccination but WITH medication?
I used successfully Budesonide (and Ivermectin but this is another story) with lots of supplements, good food etc while no one in the medical community, media, and people referred to it, why?
https://www.google.com/search?q=budeson ... e&ie=UTF-8
I used successfully Budesonide (and Ivermectin but this is another story) with lots of supplements, good food etc while no one in the medical community, media, and people referred to it, why?
https://www.google.com/search?q=budeson ... e&ie=UTF-8
Re: Coronavirus (COVID-19) Research
Covid infection increases B-amyloid pathology and dementia risk.
Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection
Nat Med. 2025 Mar;31(3):797-806.
Previous studies have suggested that systemic viral infections may increase risks of dementia. Whether this holds true for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infections is unknown. Determining this is important for anticipating the potential future incidence of dementia. To begin to do this, we measured plasma biomarkers linked to Alzheimer's disease pathology in the UK Biobank before and after serology-confirmed SARS-CoV-2 infections. SARS-CoV-2 infection was associated with biomarkers associated with β-amyloid pathology: reduced plasma Aβ42:Aβ40 ratio and, in more vulnerable participants, lower plasma Aβ42 and higher plasma pTau-181. The plasma biomarker changes were greater in participants who had been hospitalized with COVID-19 or had reported hypertension previously. We showed that the changes in biomarkers were linked to brain structural imaging patterns associated with Alzheimer's disease, lower cognitive test scores and poorer overall health evaluations. Our data from this post hoc case-control matched study thus provide observational biomarker evidence that SARS-CoV-2 infection can be associated with greater brain β-amyloid pathology in older adults. While these results do not establish causality, they suggest that SARS-CoV-2 (and possibly other systemic inflammatory diseases) may increase the risk of future Alzheimer's disease.
[Free full text]
Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection
Nat Med. 2025 Mar;31(3):797-806.
Previous studies have suggested that systemic viral infections may increase risks of dementia. Whether this holds true for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infections is unknown. Determining this is important for anticipating the potential future incidence of dementia. To begin to do this, we measured plasma biomarkers linked to Alzheimer's disease pathology in the UK Biobank before and after serology-confirmed SARS-CoV-2 infections. SARS-CoV-2 infection was associated with biomarkers associated with β-amyloid pathology: reduced plasma Aβ42:Aβ40 ratio and, in more vulnerable participants, lower plasma Aβ42 and higher plasma pTau-181. The plasma biomarker changes were greater in participants who had been hospitalized with COVID-19 or had reported hypertension previously. We showed that the changes in biomarkers were linked to brain structural imaging patterns associated with Alzheimer's disease, lower cognitive test scores and poorer overall health evaluations. Our data from this post hoc case-control matched study thus provide observational biomarker evidence that SARS-CoV-2 infection can be associated with greater brain β-amyloid pathology in older adults. While these results do not establish causality, they suggest that SARS-CoV-2 (and possibly other systemic inflammatory diseases) may increase the risk of future Alzheimer's disease.
[Free full text]
Re: Coronavirus (COVID-19) Research
Covid infection leads to miroglial dysfunction and neuropathology.
Microglia dysfunction, neurovascular inflammation and focal neuropathologies are linked to IL-1- and IL-6-related systemic inflammation in COVID-19
Nat Neurosci. 2025 Mar;28(3):558-576.
COVID-19 is associated with diverse neurological abnormalities, but the underlying mechanisms are unclear. We hypothesized that microglia, the resident immune cells of the brain, are centrally involved in this process. To study this, we developed an autopsy platform allowing the integration of molecular anatomy, protein and mRNA datasets in postmortem mirror blocks of brain and peripheral organ samples from cases of COVID-19. We observed focal loss of microglial P2Y12R, CX3CR1-CX3CL1 axis deficits and metabolic failure at sites of virus-associated vascular inflammation in severely affected medullary autonomic nuclei and other brain areas. Microglial dysfunction is linked to mitochondrial injury at sites of excessive synapse and myelin phagocytosis and loss of glutamatergic terminals, in line with proteomic changes of synapse assembly, metabolism and neuronal injury. Furthermore, regionally heterogeneous microglial changes are associated with viral load and central and systemic inflammation related to interleukin (IL)-1 or IL-6 via virus-sensing pattern recognition receptors and inflammasomes. Thus, SARS-CoV-2-induced inflammation might lead to a primarily gliovascular failure in the brain, which could be a common contributor to diverse COVID-19-related neuropathologies.
[Free full text]
Microglia dysfunction, neurovascular inflammation and focal neuropathologies are linked to IL-1- and IL-6-related systemic inflammation in COVID-19
Nat Neurosci. 2025 Mar;28(3):558-576.
COVID-19 is associated with diverse neurological abnormalities, but the underlying mechanisms are unclear. We hypothesized that microglia, the resident immune cells of the brain, are centrally involved in this process. To study this, we developed an autopsy platform allowing the integration of molecular anatomy, protein and mRNA datasets in postmortem mirror blocks of brain and peripheral organ samples from cases of COVID-19. We observed focal loss of microglial P2Y12R, CX3CR1-CX3CL1 axis deficits and metabolic failure at sites of virus-associated vascular inflammation in severely affected medullary autonomic nuclei and other brain areas. Microglial dysfunction is linked to mitochondrial injury at sites of excessive synapse and myelin phagocytosis and loss of glutamatergic terminals, in line with proteomic changes of synapse assembly, metabolism and neuronal injury. Furthermore, regionally heterogeneous microglial changes are associated with viral load and central and systemic inflammation related to interleukin (IL)-1 or IL-6 via virus-sensing pattern recognition receptors and inflammasomes. Thus, SARS-CoV-2-induced inflammation might lead to a primarily gliovascular failure in the brain, which could be a common contributor to diverse COVID-19-related neuropathologies.
[Free full text]